ANKE BIO(SZ:300009) Xin Lang Zheng Quan·2025-11-12 10:05Core Insights - Anke Bioengineering (Anke Bio) held an investor meeting on November 11, 2025, attracting 48 institutions including major funds and securities firms [1][2] - The meeting focused on the company's core product development progress and strategic planning, with key executives participating in discussions with investors [1] Product Development Progress - Anke Bio's subsidiary, Boshengji, is advancing in the innovative drug sector with five major platforms: - CD7-CAR-T (PA3-17 injection) is in critical Phase II clinical trials for T-ALL/LBL indications [3] - in vivo CAR-T (LV009) has initiated patient enrollment and is designed for B-ALL/NHL and autoimmune diseases [3] - NKCE platform is in animal testing for dual-specificity NKB69 and NKB61 targeting autoimmune diseases [3] - UCAR-Vδ1T platform has received CDE clinical trial approval for UTAA09 injection and is in animal testing for UTAA61 injection targeting solid tumors [3] - PD-1 agonist is in preclinical stages with promising data presented at the 2025 American Rheumatology Conference [3] Investor Focus and Responses - The company aims to complete patient enrollment for CD7-CAR-T within one year and plans to submit a pre-NDA communication by Q1 2027 [4] - Expansion into additional indications post-approval for T-ALL/LBL is planned, including peripheral T-cell lymphoma and acute myeloid leukemia [4] - The international strategy includes direct registration in Belt and Road countries and potential collaborations for clinical trials in Europe and the U.S. [4] R&D Strategy - Anke Bio employs a dual approach in drug development, focusing on both independent research and strategic partnerships to accelerate product maturity [6] - Collaborations include exclusive agreements for products like long-acting follicle-stimulating hormone and growth hormone with domestic leading research teams [6] - The investor meeting highlighted the company's technological capabilities and pipeline advancements, with significant interest in CAR-T therapies [6]